Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2003
12/18/2003US20030232771 Antisense modulation of MARK3 expression
12/18/2003US20030232770 Antisense modulation of hypothetical tumor endothelial marker expression
12/18/2003US20030232769 Antisense modulation of G protein-coupled receptor 39 expression
12/18/2003US20030232767 Activating cancerous cells response to therapeutic agents, by administering cisplatin or oxaliplatin, applying ionizing radiation and hydrogen peroxide
12/18/2003US20030232762 Therapeutic treating breast cancer
12/18/2003US20030232761 Novel analogues of glucose-dependent insulinotropic polypeptide
12/18/2003US20030232759 Treatment of inner ear hair cells
12/18/2003US20030232756 A polypeptide binds to G-protein coupled receptors, use in screening, diagnosing a disease or disorder caused by signalling dysregulation
12/18/2003US20030232755 Antitumor agents, anticarcinogenic agents, replacing another amino acid at 86, 87, and 88 of the amino acid sequence
12/18/2003US20030232754 Use of GLP-1 peptides
12/18/2003US20030232753 Combined tissue factor methods for coagulation and tumor treatment
12/18/2003US20030232751 Administering calmodulin to prevent bone disorders characterized by decreased bone mass such as osteopenia and osteoporosis, as well as those suffering from non-union fractures
12/18/2003US20030232750 Indolicidin peptide analogues containing at least two basic amino acids; bactericide
12/18/2003US20030232749 Methods for SHP1 mediated neuroprotection
12/18/2003US20030232748 Insulin aspart and insulin detemir in a specific ratio; antidiabetic agent
12/18/2003US20030232745 Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
12/18/2003US20030232744 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
12/18/2003US20030232738 Increasing JAK3 (Janus kinase) action in CD4+ T lymphocytes of the patient infected with human immunodeficiency virus (HIV), wherein such CD4+ T lymphocytes express CD4 that has been ligated by gp120 on human immunodeficiency virus
12/18/2003US20030232443 Comprises oligonucleotides for controlling centromere protein B activities and expression; antisense therapy; gene expression inhibition; for treating cancer and autoimmune disorders
12/18/2003US20030232442 Comprises oligonucleotides for controlling translation initiation protein (PAZ/PIWI); antisense therapy; gene expression inhibition; for treating cancer and aberrant cellular differentiation disorders
12/18/2003US20030232441 Comprises oligonucleotides for controlling dual specificity phosphatase activities; antisense therapy; gene expression inhibition; for treating cancer, apoptotic and developmental disorder
12/18/2003US20030232440 Antisense modulation of STAT1 expression
12/18/2003US20030232439 Antisense modulation of VEGF-B expression
12/18/2003US20030232438 Antisense modulation of KOX 1 expression
12/18/2003US20030232437 Antisense modulation of VEGF-C expression
12/18/2003US20030232436 Comprises oligonucleotides for controlling endemic pemphigus foliaceus protein expression and activities; antisense therapy; gene expression inhibition; for treating skin and autoimmune disorders
12/18/2003US20030232435 Antisense modulation of amyloid beta protein precursor expression
12/18/2003US20030232434 Antisense modulation of PTPN12 expression
12/18/2003US20030232421 Protein-protein interactions in adipocyte cells (3)
12/18/2003US20030232411 Novel polypeptide, cDNA encoding the same, and use thereof
12/18/2003US20030232392 Comprises soluble liver antigen auto-antibodies; fusion proteins
12/18/2003US20030232378 Novel toll molecules and uses therefor
12/18/2003US20030232374 Involved in pathogenesis of impaired detrusor contractility; useful in the diagnosis and treatment of DERP- related conditions such as impaired detrusor contractility, urinary retention, Alzheimer's disease, cardiovascular disease and
12/18/2003US20030232373 Pth (polynucleotides and polypeptides of the peptidyl-tRNA hydrolases); utilizing pth polypeptides to screen for antibacterial compounds
12/18/2003US20030232367 Methods useful for treating or modulating angiogenesis in mammals ; diagnosis and treatment of angiogenic disorders including, but not limited to, wound healing and cancer
12/18/2003US20030232366 Polyvalent cation-sensing receptor in Atlantic Salmon
12/18/2003US20030232363 Fatty acid transport proteins
12/18/2003US20030232362 A protein which excretes cancer chemotherapeutic drugs from a cell and which confers drug- resistance on the cell, a DNA encoding the protein, a method for detecting a cell type resistant to cancer chemotherapeutic drugs
12/18/2003US20030232355 A compound containing a first and a second polymeric strands, and each strand includes a sequence of ligands covalently bound by linkeres, atleast one linker selected from an amide, thioamide, sulfinamide or sufonamide
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003US20030232347 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/18/2003US20030232336 Novel human ion channel and transporter family members
12/18/2003US20030232334 Novel compositions and methods for cancer
12/18/2003US20030232332 Novel proteins and nucleic acids encoding same
12/18/2003US20030232331 Novel proteins and nucleic acids encoding same
12/18/2003US20030232325 Contacting a host cell protein or a peptide containing a WW domain with a viral protein or peptide with an amino acid sequence corresponding to the site that binds to WW doamin, to permit binding and forming complex in presence of sample
12/18/2003US20030232323 Identifying an agents which inhibit the interaction between a PD-1 ligand and a PD-1 polypeptide, from test agents, determining whether interaction is inhibited, and such agent unable to inhibit interaction, modulates immune response
12/18/2003US20030232075 For therapy of clotting disorder
12/18/2003US20030232074 For stimulating immune activation; for screening immunostimulatory compounds
12/18/2003US20030232073 Enhanced drug delivery in transdermal systems
12/18/2003US20030232057 Method and composition for inducing tolerance to an antigenic material
12/18/2003US20030232056 Compositions and methods for the therapy and diagnosis of ovarian cancer
12/18/2003US20030232054 Novel nucleic acids and polypeptides
12/18/2003US20030232053 Administering to treat rheumatoid arthritis, cancer, restenosis
12/18/2003US20030232047 Platlet glycoprotein IB alpha fusion polypeptides and methods of use thereof
12/18/2003US20030232044 Contacting sample comprising nucleic acid molecules with hybridization probe; detecting presence of nucleic acid molecule in sample that hybridizes to probe, thereby identifying nucleic acid associated with metabolic disorder
12/18/2003US20030232043 For therapy of tylomas (calluses and fissures), helomas (corns), keratoses (papules)
12/18/2003US20030232042 For therapy of calluses and fissures, helomas (corns), keratoses (papules)
12/18/2003US20030232041 For use in food and feeds
12/18/2003US20030232037 Immunology, gene therapy
12/18/2003US20030232035 Capable of expressing a heterologous sequence in target cells; vaccines
12/18/2003US20030232034 Antisense modulation of junctional adhesion molecule 3 expression
12/18/2003US20030232033 Interferon-statin combination therapy
12/18/2003US20030232031 Method for regulating neuron development and maintenance
12/18/2003US20030232014 Mass spectrometry-based procedure for detection of amino acid modifications, such as phosphorylation; drug discovery
12/18/2003CA2790348A1 Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin f2.alpha. receptor
12/18/2003CA2497609A1 Non-peptidic brs-3 agonists
12/18/2003CA2493890A1 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003CA2490357A1 Gene therapeutic for cerebrovascular disorders
12/18/2003CA2489906A1 Androgen receptor coregulators
12/18/2003CA2489282A1 Medical device for intra-lumenal delivery of pharmaceutical agents
12/18/2003CA2489195A1 Anti-addl antibodies and uses thereof
12/18/2003CA2489153A1 Modified byrodin 1 with reduced immunogenicity
12/18/2003CA2489083A1 Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor
12/18/2003CA2489050A1 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells
12/18/2003CA2488937A1 Par-2-activating peptide derivative and pharmaceutical composition using the same
12/18/2003CA2488803A1 Use of ramoplanin to treat diseases associated with the use of antibiotics
12/18/2003CA2488744A1 Compositions and methods for the use of bcl-2 transfected neurons
12/18/2003CA2488719A1 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
12/18/2003CA2488716A1 Intracellular delivery of biological effectors
12/18/2003CA2488682A1 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
12/18/2003CA2488558A1 Prevention and reduction of blood loss
12/18/2003CA2488497A1 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003CA2488403A1 Pharmaceutical formulation
12/18/2003CA2488360A1 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
12/18/2003CA2488358A1 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
12/18/2003CA2488347A1 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003CA2488346A1 Methods and compositions for the repair and/or regeneration of damaged myocardium
12/18/2003CA2488227A1 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003CA2488218A1 Therapeutic epitopes and uses thereof
12/18/2003CA2488059A1 Non-polymeric hematopoietic cell clots for delivery of active agents
12/18/2003CA2487943A1 Methods of diagnosing & treating diabetes and insulin resistance
12/18/2003CA2487924A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003CA2487831A1 Immunogenic compositions
12/18/2003CA2487428A1 Cd200-receptor mediated modulation of bone development
12/18/2003CA2487418A1 Metalloproteinase inhibitors
12/18/2003CA2487133A1 Use of il-21 in cancer and other therapeutic applications
12/18/2003CA2487077A1 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
12/18/2003CA2486584A1 Compositions and methods for treating diabetes
12/18/2003CA2486362A1 Novel recombinant anticoagulant proteins
1 ... 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 ... 3163